A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure

Journal of Internal Medicine

Volumn 264, Issue 3, 2008, Pages 291-293

  Jung, K ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BLOOD ANALYSIS; BLOOD SAMPLING; CONGESTIVE HEART FAILURE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART TRANSPLANTATION; HEMOCONCENTRATION; HOSPITAL READMISSION; HUMAN; LETTER; PATIENT MONITORING; PLASMA; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC HEART FAILURE;

BIOLOGICAL MARKERS; BLOOD SPECIMEN COLLECTION; HEART FAILURE; HUMANS; MATRIX METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 49349084672     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2008.01952.x     Document Type: Letter

References (16)

1. Jordan A, Roldan V, Garcia M et al. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis. J Intern Med 2007 262 :385 92.
2. Zucker S, Doshi K, Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: potential clinical applications. Adv Clin Chem 2004 38 :37 85.
3. Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA. What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? Clin Chim Acta 1996 254 :97 100.
4. Jung K, Laube C, Lein M et al. Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 (MMP2; MMP9) and tissue inhibitor of metalloproteinase 2 (TIMP2) in blood. Clin Chem 1998 44 :1060 2.
5. Alby C, Ben AO, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin Chim Acta 2002 325 :183 6.
6. Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003 322 :283 6.
7. Mannello F, Luchetti F, Canonico B, Papa S. Effect of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003 49 :1956 7.
8. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005 38 :410 4.
9. Jung K, Meisser A, Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Int J Cancer 2005 116 :1000 1.
10. Meisser A, Cohen M, Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005 51 :274 6.
11. Mannello F, Tonti GA. Gelatinase concentrations and zymographic profiles in human breast cancer: matrix metalloproteinases circulating in plasma are better markers for the subclassification and early prediction of cancer: the coagulation/fibrinolysis pathways alter the release, activation and recovery of different gelatinases in serum. Int J Cancer 2007 121 :216 8.
12. Santos-Martinez MJ, Medina C, Jurasz P, Radomski MW. Role of metalloproteinases in platelet function. Thromb Res 2007 doi: (Accessed December 25, 2007).
13. Lomholt AF, Frederiksen CB, Christensen IJ, Brunner N, Nielsen HJ. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations Clin Chim Acta 2007 380 :128 32.
14. Cooper TW, Eisen AZ, Stricklin GP, Welgus HG. Platelet-derived collagenase inhibitor: characterization and subcellular localization. Proc Natl Acad Sci USA 1985 82 :2779 83.
15. Wu CY, Wu MS, Chiang EP et al. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res 2007 13 :2054 60.
16. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005 5 :285 98.